Grapheal raises EUR1.9 million to advance development of embedded biosensing technology and application in digital COVID testing and wound monitoring: Includes seed financing from Novalis Biotech and private investors, support from Bpifrance as well as non-dilutive grants

Feb 09, 2021

Grapheal, a developer of graphene-based embedded biosensors for on-site diagnostics and remote patient monitoring, announced today that it has raised a total of EUR1.9 million in equity and non-dilutive sources, including seed financing from Novalis Biotech’s Acceleration Fund, several innovation grants, and Bpifrance convertible notes and loans.